Machine signal
Active cluster sell — 4 distinct insiders, $3.9M, window ends Oct 2, 2026.
Figures computed from official regulatory filings — .
Analysttarget 56.21 USD (+27%) · consensus 4.26/5 · 14 buy · 4 hold · 1 sell
Ownershipinsiders 1.4% · institutions 107.8% · short 14.7% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Alkermes plc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
11 buys746 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Whitaker Anne Clem | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Whitaker Anne Clem | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Reed Joshua | ExerciseD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Reed Joshua | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Reed Joshua | Other | $163.2K | SEC |
| Gaffin David Joseph | Sell | $83.5K | SEC |
| Gaffin David Joseph | Sell | $97.7K | SEC |
| Hopkinson Craig C. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hopkinson Craig C. | Exercise | $123K | SEC |
| Hopkinson Craig C. | Sell | $422.9K | SEC |
| Nichols Christian Todd | Sell | $33K | SEC |
| Nichols Christian Todd | Sell | $340K | SEC |
| Jackson Blair Curtis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Jackson Blair Curtis | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hopkinson Craig C. | Exercise | $2K | SEC |
| snyderman nancy lynn MD | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| snyderman nancy lynn MD | Exercise | $1.3M | SEC |
| Hopkinson Craig C. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| snyderman nancy lynn MD | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| snyderman nancy lynn MD | Sell | $2.2M | SEC |
| Hopkinson Craig C. | Sell | $437.2K | SEC |
| Hopkinson Craig C. | Exercise | $120.4K | SEC |
| Gaffin David Joseph | Sell | $98.8K | SEC |
| snyderman nancy lynn MD | Exercise | $772K | SEC |
| Hopkinson Craig C. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |